My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Dexlansoprazole (R-Lansoprazole)
    Dexlansoprazole (R-Lansoprazole)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1638
    CAS #: 138530-94-6Purity ≥98%

    Description: Dexlansoprazole (formerly known as T168390; TAK390; Kapidex; Dexilant, R-Lansoprazole and TAK-390MR), the dextrorotatory or R-enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties by employing a novel release formulation that prolongs its absorption. Dexlansoprazole is used to treat non-erosive GERD (gastroesophageal reflux disease). 

    References: Aliment Pharmacol Ther. 2009 May 1;29(9):928-37; Clin Ther. 2010 Aug;32(9):1578-96. 

    Related CAS#:226904-00-3 (Lansoprazole sodium); 131926-98-2 (5-Hydroxylansoprazole); 131927-00-9 ( 5-hydroxylansoprazole); 138530-94-6 (Dexlansoprazole; Dexilant; Kapidex; TAK-390MR; TAK 390MR; TAK390MR); 103577-40-8 (AG-1777, EC 600-451-9, H 225/18, K-1252, Lansoprazole impurity C , Lansoprazole sulfide); 131926-99-3 (Lansoprazole sulfone; AG-1813; AG 1813; AG1813); 138530-95-7 (Levolansoprazole); 700341-80-6 (AG1812 free base; Lansoprazole disulfide active metabolite; UNII-6RI44GB0V9; AC1MIZB6; HE078804); 111712-16-4 (AG 2000); 111712-15-3 (Lansoprazole sulfenamide active metabolite; UNII-7EMR32786O)  

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)369.36
    CAS No.138530-94-6
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 74 mg/mL (200.3 mM)
    Water:<1 mg/mL
    Ethanol: 74 mg/mL (200.3 mM)
    Other info

    Chemical Name: (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole


    InChi Code: InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

    SMILES Code: O=[[email protected]@](C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C           

    SynonymsT-168390; TAK-390MR; TAK-390; T168390; TAK390; T 168390; TAK 390; Dexlansoprazole; Dexilant; Kapidex; TAK 390MR; TAK390MR

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Dexlansoprazole, constitutes >80% of circulating drug after oral administration of lansoprazole, provides lower clearance and 5-fold greater systemic exposure than the S-enantiomer following oral administration of lansoprazole. Dexlansoprazole MR is a modified release formulation of dexlansoprazole, which employs a novel Dual Delayed Release (DDR) technology that delivers the drug in two discrete phases of release, thereby inhibiting newly activated proton pumps that turn over following initial PPI inactivation of H+,K+-ATPase. Dexlansoprazole MR maintains plasma drug concentrations above the threshold level longer than lansoprazole at all doses, resulting in an optimized drug exposure-intragastric pH relationship. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H+K+-ATPase proton pump in the gastric parietal cell, inhibition of this cell membrane enzyme ultimately blocks the final step in acid production.

    In Vivo
    Animal model
    Formulation & Dosage

    Aliment Pharmacol Ther. 2009 May 1;29(9):928-37; Clin Ther. 2010 Aug;32(9):1578-96. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?